IVVD — Invivyd, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1832038 ·
Last close
$0.93
Market Cap
$275.30M
52W High
$3.07
52W Low
$0.53
ADV30
4,936,203
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 14,285,000 13,012,000 -45,820,000 -44,393,000 218,883,000 160,080,000 37,803,000
Mar 2026 13,744,000 12,712,000 -43,136,000 -41,400,000 241,742,000 184,153,000 38,692,000
Dec 2025 17,207,000 16,067,000 -12,555,000 -11,070,000 276,883,000 226,689,000 35,343,000
Sep 2025 13,129,000 12,041,000 -11,023,000 -10,470,000 139,158,000 84,967,000 46,090,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-78,718,000
Investing CF
$-737,000
Financing CF
$215,522,000
CapEx
$-881,000
Dividends Paid
—
Buybacks
$-231,000
EPS Diluted TTM
$-0.45
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-995,883,000
Inventory
$262,000
Receivables
$12,209,000
ST Investments
—
EBIT TTM
$-81,774,000
Pretax Income TTM
$-77,600,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$58,365,000
EBITDA
$-111,888,000
Free Cash Flow
$-69,950,752
Enterprise Value
$79,843,992
Total Cash
$160,080,000
Total Debt
$8,391,000
Shares Out
294,758,746
Trailing EPS
$-0.31
Book Value
$0.61
ROE
-95.9%
ROA
-45.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 53,426,000 -55,560,000 -52,489,000 276,883,000 35,343,000 241,540,000 -58,135,000
Dec 2024 25,384,000 -176,876,000 -169,925,000 129,515,000 61,976,000 67,539,000 -170,491,000
Dec 2023 0 -207,783,000 -198,643,000 229,181,000 51,713,000 177,468,000 -173,164,000
Dec 2022 0 -226,258,000 -241,317,000 383,167,000 27,197,000 355,970,000 -219,987,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55

Max Pain — expiry 2026-10-16

max pain strike: $0.50 · spot: $0.97 · call oi: 11,718 · put oi: 384
Expected Move to 2026-10-16: ±$0.47 (49.04%) — implied range $0.49 – $1.44 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LXEO Lexeo Therapeutics, Inc. $271.57M $3.31 —
FATE FATE THERAPEUTICS INC $281.58M $2.35 —
STRO SUTRO BIOPHARMA, INC. $264.97M $15.98 —
IKT Inhibikase Therapeutics, Inc. $287.44M $2.06 —
LCTX Lineage Cell Therapeutics, Inc. $260.49M $1.03 —

News headlines (Yahoo Finance, 1h cache)

3 Small-Cap Biotechs With Binary Catalysts on the Calendar
2026-09-13 14:50 · Yahoo
Invivyd to Participate in Upcoming September Investor Conferences
2026-09-08 11:01 · Yahoo
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
2026-09-01 11:01 · Yahoo
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
2026-07-06 11:01 · Yahoo
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311
2026-06-19 07:00 · Yahoo
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
2026-06-16 11:01 · Yahoo
Invivyd doses first participants in Phase 3 COVID-19 trial
2026-06-09 16:22 · Yahoo
This Invivyd Insider Increased Their Holding In The Last Year
2026-06-06 13:11 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03 11:01 · Yahoo
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
2026-06-01 11:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.